Interim recommendations for use of the CanSinoBIO Ad5-nCoV-S [recombinant] vaccine (Convidecia™) against COVID-19: interim guidance, first issued 19 May 2022
CONVIDECIA is based on a modified human adenovirus that expresses the spike S protein of SARS-CoV-2. It is administered as a single dose.
